“Mantle Cell Lymphoma Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mantle Cell Lymphoma Market.
The Mantle Cell Lymphoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Mantle Cell Lymphoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Mantle Cell Lymphoma treatment therapies with a considerable amount of success over the years.
Mantle Cell Lymphoma companies working in the treatment market are PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi – ETS, PrECOG, LLC, Acerta Pharma, and others, are developing therapies for the Mantle Cell Lymphoma treatment
Emerging Mantle Cell Lymphoma therapies in the different phases of clinical trials are- PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, and others are expected to have a significant impact on the Mantle Cell Lymphoma market in the coming years.
In May 2025, According to results from the phase 2 ECOG-ACRIN E1411 trial (NCT01415752), adding bortezomib (Velcade) to bendamustine and rituximab (Rituxan; BR) as induction therapy did not lead to improved 2-year progression-free survival (PFS) compared with BR alone in patients with mantle cell lymphoma (MCL). However, Brad S. Kahl, MD, noted that the strong 2-year PFS achieved with BR alone has established a solid foundation for future advancements in MCL treatment.
In May 2025, Brad Kahl, MD, a professor of medicine, co-chair of the SCC Protocol Review and Monitoring Committee, and director of the Lymphoma Program at Washington University School of Medicine in St. Louis, highlighted the persistent treatment challenges in mantle cell lymphoma (MCL) and stressed the importance of advancing therapeutic options for various patient populations.
In February 2025, The ROR1-targeted antibody-drug conjugate (ADC) zilovertamab vedotin (MK-2140) demonstrated antitumor efficacy and a tolerable safety profile in heavily pretreated patients with relapsed or refractory mantle cell lymphoma (MCL), based on findings from cohort A of the phase 2 waveLINE-006 trial (NCT05458297) presented at the 2024 ASH Annual Meeting.
In December 2024, Galapagos NV announced additional data from the ongoing Phase I/II ATALANTA-1 study of its CD19 CAR T-cell therapy, GLPG5101. The results, featured in an oral presentation at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, demonstrate strong efficacy and an encouraging safety profile in patients with relapsed/refractory non-Hodgkin lymphoma (R/R NHL). Most patients in the study received GLPG5101 as a fresh, fit, stem-like, early memory CD19 CAR T-cell therapy, with a median veinto-vein time of seven days.
In June 2024, Roche announced the US FDA granted Breakthrough Therapy Designation to Glofitamab for the treatment of Mantle Cell Lymphoma.
Mantle Cell Lymphoma Overview
Mantle Cell Lymphoma (MCL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL) that originates from B lymphocytes in the “mantle zone” of lymph node follicles. It accounts for about 3-10% of all NHL cases. MCL typically affects middle-aged to older adults, with a higher prevalence in males.
The disease is characterized by genetic mutations, most commonly the overexpression of cyclin D1, due to a chromosomal translocation (t(11;14)(q13;q32)). Symptoms may include swollen lymph nodes, fatigue, fever, night sweats, and unintentional weight loss. It may also affect the bone marrow, spleen, and gastrointestinal tract.
MCL is generally considered challenging to treat due to its tendency to relapse. Treatment options include chemotherapy, targeted therapies (such as BTK inhibitors like ibrutinib), immunotherapy, and stem cell transplantation. Ongoing research is focused on developing novel targeted treatments to improve patient outcomes.
Get a Free Sample PDF Report to know more about Mantle Cell Lymphoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mantle-cell-lymphoma-pipeline-insight
Emerging Mantle Cell Lymphoma Drugs Under Different Phases of Clinical Development Include:
PEP07: PharmaEngine
LP-168: Jiangsu Hansoh Pharmaceutical
GLPG5101: Galapagos NV
Zamtocabtagene autoleucel: Miltenyi Biomedicine
Glofitamab: Roche
Lenalidomide: Celgene
Obinutuzumab: The Lymphoma Academic Research Org
Pirtobrutinib: Loxo Oncology
Ibrutinib: Janssen R&D
BGB-11417: BeiGene
Everolimus: Novartis
Venetoclax: Fondazione Italiana Linfomi – ETS
Ixazomib: PrECOG, LLC
Acalabrutinib: Acerta Pharma
Mantle Cell Lymphoma Route of Administration
Mantle Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Mantle Cell Lymphoma Molecule Type
Mantle Cell Lymphoma Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Mantle Cell Lymphoma Pipeline Therapeutics Assessment
Mantle Cell Lymphoma Assessment by Product Type
Mantle Cell Lymphoma By Stage and Product Type
Mantle Cell Lymphoma Assessment by Route of Administration
Mantle Cell Lymphoma By Stage and Route of Administration
Mantle Cell Lymphoma Assessment by Molecule Type
Mantle Cell Lymphoma by Stage and Molecule Type
DelveInsight’s Mantle Cell Lymphoma Report covers around 22+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Mantle Cell Lymphoma product details are provided in the report. Download the Mantle Cell Lymphoma pipeline report to learn more about the emerging Mantle Cell Lymphoma therapies
Some of the key companies in the Mantle Cell Lymphoma Therapeutics Market include:
Key companies developing therapies for Mantle Cell Lymphoma are – InnoCare Pharma Inc., Guangzhou Lupeng Pharmaceutical Company LTD., BeiGene, Nurix, LegoChem Biosciences, AbbVie, Adicet Bio, Xynomic Pharmaceuticals, Merck & Co, Incyte Corporation, TG Therapeutics, Janssen/Pharmacyclics, Eternity Bioscience, Traws Pharm, and others.
Mantle Cell Lymphoma Pipeline Analysis:
The Mantle Cell Lymphoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Mantle Cell Lymphoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mantle Cell Lymphoma Treatment.
Mantle Cell Lymphoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Mantle Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mantle Cell Lymphoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Mantle Cell Lymphoma drugs and therapies
Mantle Cell Lymphoma Pipeline Market Drivers
Expanding Access and Regulatory Support, Advancements in Therapeutics, are some of the important factors that are fueling the Mantle Cell Lymphoma Market.
Mantle Cell Lymphoma Pipeline Market Barriers
However, Complex Treatment Landscape, Limited Biomarker Availability, and other factors are creating obstacles in the Mantle Cell Lymphoma Market growth.
Scope of Mantle Cell Lymphoma Pipeline Drug Insight
Coverage: Global
Key Mantle Cell Lymphoma Companies: PharmaEngine, Jiangsu Hansoh Pharmaceutical, Galapagos NV, Miltenyi Biomedicine, Roche, Celgene, The Lymphoma Academic Research Org, Loxo Oncology, Janssen R&D, BeiGene, Novartis, Fondazione Italiana Linfomi – ETS, PrECOG, LLC, Acerta Pharma, and others
Key Mantle Cell Lymphoma Therapies: PEP07, LP-168, GLPG5101, Zamtocabtagene autoleucel, Glofitamab, Lenalidomide, Obinutuzumab, Pirtobrutinib, Ibrutinib, BGB-11417, Everolimus, Venetoclax, Ixazomib, Acalabrutinib, and others
Mantle Cell Lymphoma Therapeutic Assessment: Mantle Cell Lymphoma current marketed and Mantle Cell Lymphoma emerging therapies
Mantle Cell Lymphoma Market Dynamics: Mantle Cell Lymphoma market drivers and Mantle Cell Lymphoma market barriers
Request for Sample PDF Report for Mantle Cell Lymphoma Pipeline Assessment and clinical trials
Table of Contents
1. Mantle Cell Lymphoma Report Introduction
2. Mantle Cell Lymphoma Executive Summary
3. Mantle Cell Lymphoma Overview
4. Mantle Cell Lymphoma- Analytical Perspective In-depth Commercial Assessment
5. Mantle Cell Lymphoma Pipeline Therapeutics
6. Mantle Cell Lymphoma Late Stage Products (Phase II/III)
7. Mantle Cell Lymphoma Mid Stage Products (Phase II)
8. Mantle Cell Lymphoma Early Stage Products (Phase I)
9. Mantle Cell Lymphoma Preclinical Stage Products
10. Mantle Cell Lymphoma Therapeutics Assessment
11. Mantle Cell Lymphoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Mantle Cell Lymphoma Key Companies
14. Mantle Cell Lymphoma Key Products
15. Mantle Cell Lymphoma Unmet Needs
16 . Mantle Cell Lymphoma Market Drivers and Barriers
17. Mantle Cell Lymphoma Future Perspectives and Conclusion
18. Mantle Cell Lymphoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
